CAMELI, PAOLO
 Distribuzione geografica
Continente #
EU - Europa 6.651
NA - Nord America 5.208
AS - Asia 558
OC - Oceania 12
SA - Sud America 11
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 6
Totale 12.455
Nazione #
US - Stati Uniti d'America 5.181
IE - Irlanda 1.697
GB - Regno Unito 1.535
IT - Italia 1.437
SE - Svezia 696
FR - Francia 351
CN - Cina 281
DE - Germania 257
FI - Finlandia 208
UA - Ucraina 162
BE - Belgio 132
ES - Italia 102
IN - India 83
VN - Vietnam 76
IR - Iran 28
CA - Canada 24
HK - Hong Kong 16
PK - Pakistan 14
RU - Federazione Russa 13
TR - Turchia 13
AU - Australia 12
KR - Corea 11
JP - Giappone 9
CH - Svizzera 8
PL - Polonia 8
MK - Macedonia 7
AT - Austria 6
EU - Europa 6
HU - Ungheria 6
NL - Olanda 6
NG - Nigeria 5
ID - Indonesia 4
AR - Argentina 3
BR - Brasile 3
MX - Messico 3
PH - Filippine 3
PT - Portogallo 3
BD - Bangladesh 2
CL - Cile 2
CO - Colombia 2
CY - Cipro 2
CZ - Repubblica Ceca 2
EG - Egitto 2
IS - Islanda 2
KZ - Kazakistan 2
LT - Lituania 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SG - Singapore 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
PE - Perù 1
SA - Arabia Saudita 1
SI - Slovenia 1
SL - Sierra Leone 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 12.455
Città #
Dublin 1.666
Southend 1.445
Chandler 733
Fairfield 726
Ashburn 505
Woodbridge 321
Siena 318
Wilmington 302
Houston 278
Seattle 252
Princeton 230
Cambridge 227
Helsinki 193
New York 149
Ann Arbor 147
Brussels 132
Jacksonville 101
Florence 93
Shanghai 85
San Mateo 76
Beijing 75
Dong Ket 75
Málaga 73
Fremont 70
Milan 65
San Diego 64
Dearborn 51
Rome 38
London 36
Washington 31
Gavirate 26
Boardman 20
Gießen 19
Nanjing 18
Guangzhou 17
Tarazona 17
Chicago 14
Hyderabad 13
Redwood City 13
Norwalk 12
Toronto 12
Zanjan 12
Aachen 11
Naples 11
Chianciano Terme 10
Comun Nuovo 10
Nanchang 10
Grosseto 9
Izmir 9
Kilburn 9
Lahore 9
Pisa 9
Bangalore 8
Hong Kong 8
Leawood 8
Livorno 8
Padova 8
Prato 8
San Francisco 8
Brescia 7
Carrara 7
Pune 7
Salerno 7
San Casciano in Val di Pesa 7
Barcelona 6
Bergamo 6
Bologna 6
Bonndorf 6
Budapest 6
Cagliari 6
Falkenstein 6
Hefei 6
Melbourne 6
Paris 6
Rubano 6
Verona 6
Vienna 6
Zhengzhou 6
Amsterdam 5
Andover 5
Catania 5
Changsha 5
Dallas 5
Gdynia 5
Jiaxing 5
Jinan 5
Lappeenranta 5
Mumbai 5
Phoenix 5
Scandicci 5
Winnipeg 5
Arese 4
Arezzo 4
Bari 4
Central 4
Chieti 4
Chiswick 4
Düsseldorf 4
Fiesole 4
Gunzenhausen 4
Totale 9.123
Nome #
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 192
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 187
Exhaled nitric oxide in interstitial lung diseases 182
Peripheral biomarkers' panel for severe COVID-19 patients 177
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 176
null 171
Genetic mechanisms of critical illness in COVID-19 171
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 170
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 165
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 161
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 156
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 151
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 147
NK and NKT-like cells in granulomatous and fibrotic lung diseases 143
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 142
Incremental value of pocket-sized imaging device for bedside diagnosis of unilateral pleural effusions and ultrasound-guided thoracentesis. 140
null 134
Serum amyloid A in patients with idiopathic pulmonary fibrosis 131
Prognostic bioindicators in severe COVID-19 patients 129
Comparison of Right Versus Left Ventricular Strain Analysis as a Predictor of Outcome in Patients With Systolic Heart Failure Referred for Heart Transplantation 128
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 126
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 125
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 120
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 118
null 116
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 115
null 113
Traditional and Novel Imaging of Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction 111
null 111
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. 109
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 108
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 108
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 107
null 106
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 106
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 105
Serum amyloid A: A potential biomarker of lung disorders 104
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 104
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 104
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 102
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 102
Valutazione dell'ossido nitrico nell'esalato delle polmoniti interstiziali idiopatiche 101
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 101
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 101
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 100
Omalizumab treatment in Samter's triad: case series and review of the literature 97
Effects of rituximab therapy on B cell differentiation and depletion 97
ACUTE HF score, a multiparametric prognostic tool for acute heart failure: A real-life study 97
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 97
Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients 96
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 94
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 93
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 93
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 92
Safe performance of echocardiography during the COVID-19 pandemic: A practical guide 91
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 90
Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation 90
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 89
Mapping the human genetic architecture of COVID-19 89
Pulse oximetry oxyhemoglobin saturation in patients with idiopathic pulmonary fibrosis 88
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 88
A first update on mapping the human genetic architecture of COVID-19 87
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 87
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 85
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 85
Basic and advanced echocardiography in advanced heart failure: an overview 84
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 83
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 82
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 81
WES profiling of COVID-19 81
Pathogen-sugar interactions revealed by universal saturation transfer analysis 79
Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication 79
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 77
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 76
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 76
Immunologic responses to antifibrotic treatment in IPF patients 76
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 76
An explainable model of host genetic interactions linked to COVID-19 severity 75
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 75
Usefulness of echocardiography to detect cardiac involvement in COVID-19 patients 75
null 75
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 74
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 74
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 74
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 73
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 73
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 70
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 69
Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life 68
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 67
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 67
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 67
Clinical phenotyping in sarcoidosis management 67
The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib 67
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 64
null 63
COVID-19 and the burning issue of drug interaction: Never forget the ECG 63
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 63
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 62
null 61
Totale 10.237
Categoria #
all - tutte 49.918
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.918


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019243 0 0 0 0 0 0 0 0 24 46 94 79
2019/20201.073 67 39 33 114 90 97 96 135 113 112 71 106
2020/20212.752 90 113 141 352 297 298 211 344 265 174 239 228
2021/20222.566 187 276 225 179 123 117 113 123 118 320 273 512
2022/20233.166 206 352 396 318 193 524 273 290 241 132 141 100
2023/20243.084 137 122 347 195 248 778 1.002 204 51 0 0 0
Totale 13.057